Summary of UNICEF Study: A Commercial Perspective of Vaccine Study

SENT BY:NAT'L VACCINE PROGRAM; 7-25-94; 17:18; 12024018141-' 916199424979;# 5
(EPI vaccines: BCG, DTP, TT, measles, OPV) is estimated to be
roughly $1 billion. This represents one third of the total world
vaccine market which is estimated at $3 billion. Another -third
is comprised Of proprietary products such as Hib, Hepatitis B,
and Hepatitis A. While UNICEF and PAHO are purchasing roughly
50% of the industrialized suppliers' output of EPI vaccines, this
represents less than 5% of the global revenue opportunity.

Figure 3 World Vaccine Market by Product
Source: Analyst Reports, Company Reports, WHO, Mercer Analysis

The $3 billion market estimate is significantly larger than. other quoted market estimates. After years of stagnating or
diminishing revenues, the world vaccine market is now growing
rapidly due to a new generation of proprietary products such as
Hib, Hepatitis B, and Hepatitis A. These products have
revitalized the vaccine industry and motivated manufacturers not
only to continue producing vaccine but even to invest to
strengthen their competitive position. A series of agreements
and acquisitions has provided manufacturers with broader product
portfolios, increased geographic access and stronger R&D capacity
(See Appendix 3).
Manufacturers can be broadly classified into three groups:

5